Replies to post #107678 on Biotech Values

[DewDiligence]

Nothing from AASLD leads me to think Boceprevir has narrowed the gap relative to Telaprevir. MRK needs to find a sustainable marketing angle to avert having Boceprevir become a commercial bust. Comments?